Solid Malignancies clinical trials at University of California Health

3 in progress, 2 open to eligible people

Showing trials for

  • GIM-122 in Subjects With Advanced Solid Malignancies

    open to eligible people ages 18 years and up

    GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.

    at UCLA UCSF

  • AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

    open to eligible people ages 18-130

    This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.

    at UCLA UCSF

  • CFI-402411 in Subjects With Advanced Solid Malignancies

    Sorry, in progress, not accepting new patients

    The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.

    at UCSD

Our lead scientists for Solid Malignancies research studies include .

Last updated: